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Parkinson’s disease (PD) is a debilitating, neurodegenerative disorder that affects nearly
one million people. It’s hallmark signs and symptoms include slow movements, rigidity,
tremor, and unstable posture. Additionally, non-motor symptoms such as sleeplessness,
depression, cognitive impairment, impulse control behaviors (ICB) have been reported.
Today, treatment regimens to modify disease progression do not exist and as such,
treatment is focused on symptom relief. Additionally, physicians are challenged to base
their diagnoses and treatment plans on unreliable self-reported symptoms, even when
used in conjunction to validated assessments such as the Unified Parkinson’s Disease
Rating Scale (UPDRS) and clinical exams. Wearable technology may provide clinicians
objective measures of motor problems to supplement current subjective methods.
Global Kinetics Corporation (GKC) has developed a watch-device called the Personal
KinetiGraph (PKG) that records movements and provides patients medication dosing
reminders. A separate clinician-use report supplies longitudinal motor and event data.
The PKG was FDA-cleared in September 2016. We studied 63 PD patients during
85 routine care visits in 2 US academic institutions, evaluating the clinical utility of the
PKG. Patients wore a PKG for 6 continuous days before their visit. Next, PKG data was
uploaded to produce a report. In clinic, physicians discussed PD symptoms with patients
and conducted a motor examination prior to reviewing the PKG report and comparing it
to their initial assessments. Lastly, patient, caregiver and physician satisfaction surveys
were conducted by each user. Across all visits when patients did not report bradykinesia
or dyskinesia, the PKG reported these symptoms (50 and 33% of the time, respectively).
The PKG provided insights for treatment plans in 50 (79%) patients across 71 (84%)
visits. Physicians found improved patient dialogue in 50 (59%) visits, improved ability to
assess treatment impact in 32 (38%) visits, and improved motor assessment in 28 (33%)
visits. Patients stated in 82% of responses that they agreed or strongly agreed in PKG
training, usability, performance, and satisfaction. In 39% of responses, they also reported
a very valuable impact on their care. PKG use in 63 PD patients within our clinical practice
showed clinically relevant utility in many areas.
Keywords: neurology, movement disorder, Parkinson’s disease, digital health, personal Kinetigraph, objective
measurement
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INTRODUCTION
PD is a progressive, neurodegenerative disease causingmotor and
non-motor symptoms such as tremor, rigidity, slow movements,
and postural instability (1). Non-motor symptoms may include
sleep disturbances, bladder and bowel dysfunction, and cognitive
impairment (2). To date, no intervention has shown efficacy
or is designated as being useful in clinical practice as a
means of preventing or slowing PD disease progression and
as such treatment is focused on symptom management (3).
Treatment regimens rely on assessments such as the UPDRS
and clinical exams. Both include patient -reported symptoms
which are often inaccurate or incomplete (4). currently affects
approximately one million people in the United States with an
anticipated large increase in the near future. The Parkinson’s
Foundation Prevalence Project estimates that 930,000 people
in the United States will be living with PD by the year
2020. This number is predicted to rise to 1.2 million by
2030 (5). The main motor related symptoms of Parkinson’s
disease are bradykinesia, rigidity, tremor, and postural instability.
Other potential manifestations are myriad and may include
autonomic, behavioral, cognitive, olfactory, sensory, sleep, and
visually related dysfunctions, now encapsulated in the moniker,
“Non-Motor Manifestations of Parkinson disease” (1). Although
PD has common, basic motor phenomena, the phenotype is
highly variable.
Most of the current therapies for PD are directed toward
reducing rigidity, improving bradykinesia and consequently
improving mobility. Tremor, however, is poorly understood (6).
Since the introduction of L-DOPA use in PD in the late 1960’s
by George Cotzias and collaborators, it has remained the gold-
standard of medical therapy. Despite the robust and consistent
benefits in early disease, advanced patients often experience
motor fluctuations (due to the short drug half-life), L-DOPA-
induced dyskinesias and varied absorption with dose failures
(1). As time passes the interval of benefit from levodopa often
shortens, resulting in so-called “wearing off,” and the response
may be less predictable, with “off” episodes not clearly associated
with medication timing. Levodopa-induced dyskinesias occur in
up to 80% of patients with Parkinson’s after a few years of chronic
treatment (7). Impulse control behaviors (ICB) are recognized
as non-motor complications of dopaminergic medications in
patients with Parkinson’s disease (8). Therefore, treatment of
non-motor symptoms requires monitoring when medications
are either adjusted or other therapies are introduced. The
clinician’s challenge becomes providing recommendations for
medication regimens that address these problems without being
unrealistically complicated or provocative of intolerable side
effects. This is not a simple task. Treatment recommendations
are further complicated by the clinician’s dependence upon
information provided by the patient and their care partner
regarding the timing of symptoms, or correctly identifying
symptoms, e.g., whenmobility is poor, or discrimination between
tremor and dyskinesia. Lastly, a well-known phenomenon
among clinicians is that patients tend to do better during their
appointments and their examination does not necessarily reflect
their performance at home: “Why don’t you walk like that when
we are at home?” is an often-heard comment from spouses.
A moment’s reflection reveals what an archaic, inaccurate and
frustrating process the current method of PD patient evaluation
and treatment is for all concerned.
Formal clinical assessment tools such as the Unified
Parkinson’s Disease Rating System (UPDRS), and questionnaires
such as Parkinson’s Disease Questionnaire−39 (PDQ-39), 24-h
motor diaries also have well-known limitations (9, 10).
Advanced cases requiring invasive PD therapies of intrajejunal
infusion of carbidopa/levodopa (Duopa in the U.S., Duodopa
elsewhere) and Deep Brain Stimulation (DBS) require thoughtful
patient selection based upon levodopa responsiveness and well-
characterized motor problems, including motor fluctuations or
troublesome tremor (11).
In a systematic review of existing technologies Rovini et al.
(12), included 147 articles in their analysis. They abstracted
data from the papers and considered: the used technological
solutions and typology of sensors, their placement over the body
and the sampling frequency; the experimental protocol adopted;
the subjects involved, according to their pathology and their
health status; the performed analysis, including the extracted
features, the applied statistical methods, the implemented
classifiers and the main findings for each work. Particular
attention was focused on the classifiers performance because
they can synthetically represent the robustness of the technology
proposed for a specific PD application. They identified several
key characteristics of reliable and accurate wearable sensors and
algorithms: a 3-axis accelerometer and power spectral density for
signal interpretation.
The Personal KinetiGraph (PKG) System was developed
by neurologists at the Melbourne-based Florey Institute of
Neuroscience and Mental Health in response to the lack
of objective measurement tools for movement disorders
symptoms. It is intended to quantify kinematics of movement
disorder symptoms in conditions such as PD, including
tremor, bradykinesia, and dyskinesia. It includes a medication
reminder, medication administration marker, and is intended
to monitor activity associated with movement during sleep.
The system is indicated for use in individuals 46–83 years
of age and was FDA-cleared in September 2016 (13). The
PKG System consists of the PKG watch (Figure 1) and PKG
Report (Figure 2).
The PKG watch is a wrist-worn medical device that looks like
a wristwatch. It is programmed and dispensed by clinic staff and
worn by the patient for 6–10 full days. During this wear time, the
PKG watch automatically collects data on the type of movement
experienced by the patient and reminds the patient to register
when they have taken dopaminergic medications as prescribed by
their physician. A proprietary mathematical algorithm translates
the raw movement data collected by the PKG watch into a PKG
report. It is intended that the physician use the PKG as an
additional tool for clinical care. We investigated this system to
assess its clinical utility in capturing motor problems within the
patient’s home setting, in improving dialogue with the patient,
and its impact on treatment recommendations.
The PKG has been studied by various investigators. It is our
intent to build upon these earlier research efforts.
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METHODS AND MATERIALS
Study Design
This was a single-arm, open-labeled, investigator-sponsored,
observational study conducted at two US academic institutions:
University of California, Irvine (UCI) and University of
California, Los Angeles (UCLA). Each investigational site’s local
University Institutional Review Board reviewed and approved the
study protocol prior to subject enrollment.
Objectives
The primary purpose of this study was to evaluate the clinical
utility of the PKG Movement Recording System when used in
routine clinical care of patients with PD. Secondary objectives
included PKG performance and user satisfaction.
Study Population
Active patient charts within each practice were used to identify
potential subjects. Male and female patients with PD, between
46 and 83 years of age at the time of consent, responsive to
FIGURE 1 | PKG watch.
dopaminergic therapy and were walking without routine use of a
walking-aid were included. Patients with psychosis were excluded
from study participation. Subjects were consented either in
person or by phone. Each subject could take home, review, and
ask questions regarding the Informed Consent Form and study.
During the study subjects were treated according to each
clinician’s standard practice and for no <90 days.
Endpoints
The primary endpoint was the frequency of disagreement of PD
symptoms reported by the patient vs. the PKG Report.
Secondary Endpoints Were:
1. Frequency of treatable findings per clinician’s assessment of
PKG report
2. Frequency of PKG report use in treatment change decisions
3. Global impression of improvement
4. Global impact on patient care
5. PKG subject and caregiver satisfaction
6. PKG Scores: Fluctuation Score, Bradykinesia Score,
Dyskinesia Score.
Device Description
The PKG System was developed in response to the lack
of objective measurement tools for movement disorders
symptoms. It is intended to quantify kinematics of movement
disorder symptoms in conditions such as PD, including
tremor, bradykinesia, and dyskinesia. Its functionality measures
acceleration of the wrist and includes a medication reminder,
medication administration marker. It is intended to monitor
activity associated with movement, including movement during
sleep. The system is indicated for use in individuals 46–83 years
of age and was FDA-cleared in September 2016. The PKG System
consists of the PKGwatch (Figure 1) and PKGReport (Figure 2).
The PKG is worn like a wrist watch (on the most affected
side), weighs 35 g, and contains a rechargeable battery and a 3-
axis iMEMS accelerometer (ADXL345 Analog Devices) set to
FIGURE 2 | PKG report.
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record 11-bit digital measurement of acceleration with a range
of ±4 g and sampling rate of 50 samples per second using a
digital micro-controller and data storage on flash memory. It
is programmed and dispensed by clinic staff and worn by the
patient for 6–10 full days. During this wear time the PKG watch
automatically collects data on the type of movement experienced
by the patient and reminds the patient to register when they
have taken dopaminergic medications as prescribed by their
physician. The acceleration recordings were divided into 2-min
epoch and the inputs to the expert system includedMean Spectral
Power (MSP) within bands of acceleration between 0.2 and
4Hz, peak acceleration and the amount of time within these
epochs that there was no movement. The algorithm similarly
recognizes dyskinesia as having movements of normal amplitude
and acceleration but with shorter periods without movement.
Off periods are correlated with dose administration. Off periods
are seen as bradykinesia half an hour prior to medication
administration, but differentiated from true bradykinesia when
dyskinesias appear 1 h afterwardmedication administration. This
proprietary mathematical algorithm that was developed using a
fuzzy logic approach, the spectral power of the low frequencies of
an accelerometer trace and with iterative modeling and retesting
of new subjects translates the raw movement data collected by
the PKG watch into bradykinesia and dyskinesia scores and a
graphical PKG report (14).
Questionnaires
Two surveys to help assess clinical utility were administered
during the course of the study: (1) Global Impact on Patient Care
and (2) PKG Patient/Caregiver Survey:
Global Impact on Patient Care–
This survey was completed by physicians at the end of a patient’s
study participation in order to determine if and how the PKG
system impacted various aspects of the patient’s clinical care,
including patient education. It consisted of two subparts: Global
Impact on Patient Care (addressing overall impact on patient
care) and Clinical Global Impression of Improvement (overall
impression on patient improvement). Examples of questions
asked of physicians included:
• Improved dialogue with patient?
• Improved patient education about illness?
• Improved patient education about symptoms?
• Improved ability to assess impact of a therapy?
• Improved ability to assess patient PD symptoms?
The complete set of questions and results for subpart Global
Impact on Patient Care can be found in Table 5. Subpart Clinical
Global Impression of Improvement could not be completed since
the majority of subjects did not require a follow-up visit per their
treatment plan.
PKG Patient/Caregiver Survey
Subjects and their caregivers were asked to complete a three-
part questionnaire to address (1) PKG Use (product usability),
(2) the PKG Impact on Patient Care, and (3) Patient Global
Impression (patient overall impression). Examples of questions
asked subjects and their caregivers included:
• Was the training received on the use of the PKG adequate?
• Was the PKG easy to use?
• Did PKG medication reminders assist you in taking medication
on time?
• Did PKG data assist you with explaining your symptoms to
your doctor?
The complete set of questions and results for subparts PKG
Use Global Impact on Patient Care and PKG Impact on Patient
Care can be found in Tables 6, 7, respectively. Subpart Global
Impression was not analyzed due to a low response rate.
PKG Report
The PKG report is a graphical illustration of the patient’s
movement as recorded by the PKG during their 6-day wear
period (Figure 2). The PKG report provides a measure of severity
and proportion of time spent at various levels of dyskinesia and
bradykinesia in relation to timing of levodopa medication. The
main plot of the PKG report shows the median, 25 and 75%
percentile of the bradykinesia score (BKS) and dyskinesia score
(DKS) of the patient over all days of recording compared with
the BKS and DKS of a control group (non-PD patients). In
addition, a separate tremor assessment provides tremors relative
to medication administration to illustrate “off periods”1.
Procedures
All subjects were assessed according to each clinician’s standard
practice, approximately every 3 months. For 6 consecutive days
prior to a visit, patients wore a PKG watch which collected
movement data and provided medication reminders. Watches
were removed only for showering or bathing. Data from the
watches were subsequently uploaded in the clinic to generate a
PKG report. Patients who were enrolled in the study underwent
a screening examination. In each baseline and follow-up visit, the
physician followed a protocol of first assessing and interviewing
the patient while blinded to PKG data and noting treatment
adjustments. Then the PKG report was unblinded to both
the physician and patient. Upon review of the PKG data, the
physician reassessed the patient, and adjusted the treatment plan
in light of new information. Physicians recorded the change in
the treatment and plan including whether or not the decision was
based upon additional data that the PKG provided them.
Data from the PKG report was used in both primary and
secondary endpoint analyses. Safety was also assessed at each
visit. Medications were reviewed prior to enrollment and at each
visit to confirm responsiveness to dopaminergic treatment and
to adjust per revised treatment plans. Lastly, questionnaires were
administered to measure physician, patient and caregiver PKG
satisfaction rates.
PKG Scores: Fluctuation and Dyskinesia
Score (FDS), Bradykinesia Score (BKS),
Dyskinesia Score (DKS)
The proposed optimal and acceptable PKG Score targets used in
this study were based on published reports, where the FDS is
a summary score of motor fluctuation and dyskinesia, derived
1www.globalkineticscorporation.com/for-healthcare-professionals/
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TABLE 1 | Subject demographics & Medication at enrollment.
Overall Site 01 Site 02
n (%) 63 100% 42 67% 21 33%
Age
Median 68.5 68 70
(Min, Max) 43 86 54 86 43 80
Gender, n (%)
Female 26 41% 18 43% 8 38%
Male 37 59% 25 60% 12 57%
Average Duration of PD (Year) 10.8 11.8 8.8
Overall
Medication at enrollment by drug class n %
Amantadine 15 24
COMT-inhibitor 10 16
Dopamine agonist 32 51
Decarboxylase inhibitor 1 2
Duopa 1 2
Levodopa 61 97
MAOB-inhibitor 13 21
Other 5 8
as the logarithm of the sum of the interquartile range of BKS
and DKS across all days of recording and has been shown to
differentiate clinical fluctuators from non-fluctuators (10).
Bradykinesia (BKS)—Optimal: median BKS score < 23 and
FDS > 8; acceptable: median scores between 23 and 25 and/or
Fluctuations (FDS) > 7.5 with no fluctuations; Dyskinesia
(DKS)—Optimal: median DKS score < 7 and FDS < 10.8;
acceptable: median scores between 7 and 9 and FDS < 13 and
no fluctuations.
Statistical Analysis
Descriptive statistics including range, median, absolute values,
proportion of visits, and proportion of patients were used in all
analyses. A per-protocol analysis was conducted on the primary
analysis set. Data for both primary and secondary analyses
were presented as both proportion of visits and proportion
of patients.
RESULTS
Overall, information from the PKG report augmented the
patient-physician dialogue about symptoms and the physician
treatment plan decisions.
Subject Demographics: this study enrolled 63 adult patients
with Parkinson’s disease. Baseline characteristics of the study
population include a median age of subjects at 65 years
and slightly more male enrollees than females (59% vs. 41%,
respectively) (Table 1).
Number of Study Visits:
Study visits were scheduled according to routine care. In total, 85
visits’ data was used for primary and secondary analyses:
• 65 screening and enrollment visits
• 54 baseline visits
• 16 follow up #1 visits
• 8 follow up #2 visits
• 5 follow up #3 visits
• 2 follow up #4 visits
Primary Analysis
Our primary endpoint was the frequency of disagreement of
symptoms reported by the patient vs. PKG report (i.e., the
number of times a symptom was present in the PKG report and
not reported by the subject when interviewed by the investigator,
or was reported by the subject but not present in the PKG report).
Across all 85 visits, symptoms were identified by the PKG report
and not reported by the subject 30 times (35%). In contrast,
the subject reported a symptom that did not appear in the
PKG report 15 times (17.6%). Table 2a provides the distribution
of symptoms, while Table 2b provides the proportion of
patients who experienced disagreement in symptom reporting.
Bradykinesia represented 50% of the symptoms reported by the
PKG report and not by the subject. Proportionately, 48% of
patients had a PKG reporting a symptom that they had not told
their physician about and 24% of patients reported a symptom
that hadn’t appeared in the PKG report.
Secondary Analyses
Frequency of Treatable Findings Identified in PKG
Report
We measured frequency of treatable findings, and impact on
treatment plans and patient care. Table 3 shows all events in
which the PKG reported a treatable finding to the clinician for
potential action in clinical practice. Bradykinesia represented
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TABLE 2A | Frequency of disagreement in Symptom reporting between subject and PKG report across visits.
Symptoms reported by PKG report AND NOT reported by subject Symptoms reported by subject AND NOT reported by PKG report
Symptoms (n) (%) (n) (%)
Bradykinesia 15 50 6 40
Dyskinesia 10 33 6 40
Tremor 5 17 3 20
Total 30 35 15 17.6
TABLE 2B | Proportion of patients who experienced disagreement in symptom reporting between subject and PKG report.
Symptoms reported by PKG report AND NOT reported by subject Symptoms reported by subject AND NOT reported by PKG report
Symptoms (n) (%) (n) (%)
Bradykinesia 15 24 6 10
Dyskinesia 10 16 6 10
Tremor 5 8 3 5
Total 30 48 15 24
61% of all treatable findings, followed by dyskinesia as
32% of all treatable findings. Global bradykinesia requiring
one or more doses of levodopa or other treatment to be
increased was the most frequently observed subtype in 47%
of bradykinesia cases, predictable dyskinesia requiring one or
more treatments represented 44% of dyskinesia cases. In contrast,
global dyskinesia requiring a reduction in one or more doses
of levodopa, identification of impulsive-compulsive behaviors
(ICB), nighttime sleep disturbances, and non-adherence to
medication were least observed (0% of visits).
Frequency and Percentage of PKG Report Use in
Treatment Change Decisions
Data from the PKG reports was used to make 74 changes in
treatment plans across 71 (84%) visits and 50 (79%) patients.
Most common treatment changes included the addition of at least
one medication or changed dosage and timing of medications.
Levodopa equivalent doses (LED) were calculated to
determine how the PKG helped influenced treatment decisions
at Enrollment and End-of-Study (EOS). Overall, an increase of
7.9 g of LED were prescribed (average of 125 mg/patient). Most
often, however, treatment frequency or dose times were changed.
The PKG scores across all visits are provided in Table 4.
Although the objective of this study was not to treat toward
any pre-specified target, our secondary analyses included a PKG
score measurement. Per Pahwa’s et al. (10) assessment, our study
population was managed optimally at EOS with Median BKS
score < 23 (22.8), Median DKS score < 7 (2.3) and Median
FDS > 8 (8.3).
Global Impact of PKG on Patient Care
We also sought investigator’s feedback on the impact of the PKG
on patient care (Table 5). The investigators surveyed reported
that the PKG improved their dialogue with the patient in 50 visits
(59%), and improved education about their illness, symptoms,
TABLE 3 | PKG-identified treatable findings of symptoms and subtypes.
Total
(n) (%)
Bradykinesia 17 27
Global bradykinesia requiring one or
more doses of levodopa or other
treatment to be increased
8 13
Predictable bradykinesia with one or
more doses (i.e., dose related
fluctuations) requiring treatment
4 6
Unpredictable bradykinesia (e.g., off
periods) with one or more doses and/or
delayed response to some/all doses)
2 3
Early morning bradykinesia (i.e.,
bradykinesia prior to first dose of day)
3 5
Dyskinesia 9 14
Global dyskinesia requiring one or more
doses of levodopa or other treatment to
be reduced
0 0
Predictable dyskinesia with one or more
doses (i.e., peak dose dyskinesia)
requiring treatment
4 6
Unpredictable dyskinesia (off periods)
with one or more doses
2 3
Type of dyskinesia (e.g., biphasic vs.
peak)
3 5
and ability to assess patient PD symptoms in 65 visits (77%) (15,
29, and 33%, respectively).
PKG Subject and Caregiver Satisfaction
Subjects and caregivers were surveyed to better understand their
satisfaction levels with the PKG (Table 6). Of the responses, 82%
agreed or strongly agreed that the PKG was easy to learn, was
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TABLE 4 | Study PKG scores.
PKG scores
Fluctuation score (FDS)
(Optimal management FDS > 8)
Bradykinesia score (BKS)
(Optimal management BKS < 23)
Dyskinesia score (DKS)
(Optimal management FDS < 7)
Percent time
immobile (PTI)
Median 8.3 22.8 2.3 6.1
Variance 11.0 37.0 14.5 34.7
SD 3.3 6.1 3.8 5.9
Min 3.7 11.7 0.1 0.4
Max 20.9 39.9 21.9 32.8
TABLE 5 | Global impact of PKG on patient care.
Count Visits (%)
Improved dialogue with patient 50 59
Improved patient education about illness 13 15
Improved patient education about symptoms 25 29
Improved patient education about treatment use 7 8
Improved ability to assess impact of a therapy 32 38
Improved ability to assess need for additional tests or
treatments
6 7
Improved ability to assess patient PD symptoms 28 33
Avoidance/cancellation of a referral that was previously
planned
1 1
Patient referred for advanced therapy evaluation now
became optimally medically managed (avoided
advance therapy)
0 0
Other 2 2
easy to use, enabled them to confirm medication administration,
performed as expected and would use it again.
PKG Impact on My Care
In addition, subjects were surveyed to assess the PKG’s impact on
their care (Table 7). Across all questions and responses, 74% of
all responses reported the PKG to be somewhat or very valuable
in helping patients take medication on time, explain symptoms,
provide additional data to their manage care for PD. Providing
additional data about patient movement during normal daily
activities was the most favorable response.
Case Studies
One example of a patient who benefited from PKG use is
a 75-year-old female with a 7-year history of PD. She has
mild cognitive impairment (MCI) and complained of motor
fluctuations. Due to her MCI, she had difficulty reporting when
she was off and when she was dyskinetic. The PKG identified off
times in the AM and dyskinesias in the afternoon. Based on the
PKG data her regimen of carbidopa/levodopa dose was adjusted
and her symptoms markedly improved.
Another example of a patient who benefited from PKG across
multiple visits is a 58-year-old female with a 14-year history
of PD. The patient reported bradykinesia but was reluctant to
make a treatment change. After review of the PKG findings
with the patient she chose to adjust her treatment regimen. A
second PKG report at a follow-up visit characterized dyskinesias
which were then addressed by another treatment adjustment.
The patient was ultimately placed on enteral carbidopa/levodopa.
The clinician felt that the PKG report improved dialogue with
the patient, thus improving patient education about her illness
and symptoms, allowing her to make better informed decisions
about her care. The initial Patient Caregiver survey response
agreed regarding adequate training, ease of use, performance,
medication administration, and willingness to use again. At the
end of the study, the response was “Strongly Agreed” when asked
the same questions. Furthermore, the patient responded the PKG
system had a very valuable impact on her care.
Safety
Safety was assessed at each visit. No serious adverse events
or adverse device effects were reported during the course of
this study.
DISCUSSION
Treatment of PD patients is heavily reliant upon patient and
caregiver reported symptoms. Standard assessments such as
the UPDRS incorporate patient-reported symptoms to monitor
and determine disease manifestations and progression. This
may be compromised by the cognitive impact of PD, the
misidentification of symptoms (e.g., tremor vs. dyskinesia), and
the variability of symptoms. As a result, symptoms may be
misreported or underreported. With the recent proliferation of
wearable devices in healthcare, we were interested to see if the
PKG could be used in clinical practice to provide real-world data
through passive data collection and medication reminders. We
were particularly interested to see how the data might identify
symptoms that the patients had not reported, altering patient-
physician dialogue, if these data could provide an objective basis
to aid treatment decisions. Also, importantly, we wished to assess
the patient perspective on the use of the wearable device in the
management of their symptoms.
Using objective measurement (OM) to augment PD treatment
has been an area of interest for quite some time. Rovini
et al. (12) analyzed several wearable technologies in 2017 to
offer guidance on reliable features and methods. Their review
focused on wearable devices for PD applications and identified
five main fields: early diagnosis, tremor, body motion analysis,
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TABLE 6 | Patient/Caregiver survey - PKG use.
Strongly
disagree
Disagree Neutral Agree Strongly
agree
No response
The training I received on the use of the
PKG was adequate
2 1 2 26 44 10
The PKG was easy to use 2 1 0 25 47 9
The PKG performed as I expected 2 4 2 28 34 9
I was able to wear the PKG and complete
medication use confirmations as
instructed by my doctor
1 3 0 27 43 9
I would be willing to use the PKG again to
assist in the management of my PD in the
future
1 0 1 34 39 9
Count 8 9 5 140 207 46
Overall responses (%) 2 2 1 33 49 11
TABLE 7 | PKG impact on my care.
Not valuable Of little
value
Neutral Somewhat
valuable
Very
valuable
No response
PKG medication reminders assisted me
with taking my medication on time
1 1 10 30 34 9
PKG data assisted me with explaining my
symptoms to my doctor
1 3 20 27 24 8
The PKG provided data to my doctor
about my symptoms that I could not
provide
1 2 13 26 34 8
The PKG provided additional data about
my movement during normal daily
activities
0 1 4 32 38 8
The PKG provided additional data that
assisted my doctor with making decisions
about my care
0 1 9 30 36 8
The PKG provided additional data that
contributed to the overall management of
my PD
1 0 9 31 35 8
Count 4 8 65 176 201 49
Responses (%) 1 2 13 35 39 10
motor fluctuations (ON–OFF phases), and home and long-term
monitoring. Their aim was to capture observations throughout
disease progression, e.g., early symptoms upon diagnosis, during
disease progression some of the most complex conditions (i.e.,
motor fluctuations and long-term remote monitoring).
Pahwa et al. (10) published an expert review in 2018 to provide
additional recommendations on the role of the PKG in routine
clinical assessments. A group of 5 neurologists focused on the use
of the PKG as a tool to inform clinical assessment and impact
patient care. The exact clinical scenarios as documented in the
paper were:
• The poor historian: patient is unable to identify or
communicate PD symptoms or their report of the symptoms
does not match the clinical impression;
• Motor fluctuations: patient presents with motor fluctuation
symptoms of complex or uncertain pattern and severity,
and/or increased OFF-time;
• Dyskinesia: patient presents with dyskinesias of uncertain
pattern or severity, clinical impression of dyskinesia does not
match patient report, and/ormovements of uncertain etiology;
• Tremor: patient over/under reports tremor, or denies any
tremor response to medication;
• Dyskinesia vs. Tremor: patient reports involuntary movement
of unclear type, with inability to distinguish between tremor
and dyskinesias over the day, or how they are affected
by medications;
• Excessive daytime sleepiness: over/under reporting of
daytime sleepiness by patient, or incongruences between
patient/caregiver reports;
• Response to therapy change: patient is unclear about the
benefits of a therapeutic change;
• Assessment for and optimization of advanced therapies:
assessing the need for advanced therapies such as DBS
in patients with suspected motor fluctuations, dyskinesias,
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and/or tremor. Advanced therapies also provide more
complexity, making optimization more challenging;
• Telemedicine: patients who cannot be seen in
the clinic in person, leading to more limited
telemedicine-based assessments;
• New patients: any newly diagnosed PD patient or a new patient
to the clinic (10).
They concluded the PKGmay augment clinical decision-making.
For example, objective measurement helps detect uncontrolled
patients and provide data to help decide on which treatments
should be introduced or changed to optimize therapy (10).
Ultimately, they stated that the objective measures of the
PKG could confirm presence/absence of motor manifestations
(including fluctuations) as reported by the patient, provide
discussion points for physician/patient dialogue, provide interim
data between clinic visits, and finally can be used to establish a
baseline for newly diagnosed patients (10).
In 2018, Farzanehfar et al. (15) reported successful use of
the PKG in routine PD to improve outcomes by adjusting
therapy to achieve predefined target ranges of OM. In this
study, an accelerometry based measurement and predefined
target ranges were used to assess motor function in a Northern
Tasmania PD cohort managed by a Movement Disorder clinic.
Approximately 40% (n = 103) of the total PD patients within
the clinic participated in this study. Targets were set to
differentiate between controlled and uncontrolled bradykinesia
and dyskinesia. Farzanehfar’s team used targets and treatment
guidelines created by a panel of four neurologists and scientists
who were familiar with PKG use including M. Horne and K.
Kotschet. Targets as directly stated in the paper were: BKS = 23
corresponds to a UPDRS III of ∼20, and BKS = 25 to a UPDRS
III of ∼30. Bradykinesia was considered controlled if the BKS <
23 and uncontrolled if the BKS > 26. Changes in therapy were
not required if the BKS < 23. For Dyskinesia targets (where DKS
represents the median dyskinesia score for the PKG recording
period). Control was defined as a DKS< 9, which corresponds to
an Abnormal Involuntary Movement Score (AIMS) of 10. DKS
that peaked between 7 and 9 with an FDS > 13 were treated (15).
Earlier this year, Santiago et al. (16) reported the use of the
PKG in routine care of PD patients led tomedication adjustments
in approximately one third of 112 records. Physicians identified
patients in routine care for whom an objective measurement
could improve physician-patient interactions during clinic visits.
Patients wore a PKG for ≥6 days during routine daily
living activities. The survey period ran between December
2015 through July 2016 and four physicians provided survey
responses. Of 112 completed physician surveys, 46 (41%)
indicated the PKG provided relevant additional information
sufficient to consider adjusting their therapeutic management
plan; 66 (59%) indicated the PKG provided no further
information to support a therapeutic decision differing from that
made during a routine clinical evaluation. Upon further review
of these 46 surveys, 36 surveys (78%) revealed the information
provided by the PKG ultimately resulted in adjusting the patient’s
medical management (16).
We were interested in building upon these efforts by
understanding the clinical utility in practice from both the
physician and patient perspectives.
The average duration of PD in our study population was over
11 years. The patients were managed by experienced movement
disorders clinicians, and yet, with the PKG system, a 35%
improvement in motor-symptom monitoring was accomplished.
The PKG measures movement every 2min. The algorithm
utilizes medication administration event data and prolonged
immobility to distinguish between intentional immobility, e.g.,
sleep, vs. bradykinesia. It bases this calculation upon a percent-
time-immobile score that is then cross-checked against patient
responses (17). Furthermore, we felt understanding fluctuations
more accurately through empirical information would help
enhance patient dialogue and treatment planning. The use of the
PKG Fluctuation and Dyskinesia Score based upon a difference
in the interquartile ranges of patient movement was selected as a
secondary objective (18).
The clinical utility of the PKG system is supported
by both the positive patient reports of using the PKG,
and the clinicians reporting improved patient dialogue and
educational opportunity.
Future research opportunities for the PKG system in
Parkinson’s disease include:
• PKG as a replacement for patient diaries in clinical
trials assessing on-time, off-time, quality of on-time,
and dyskinesias;
• Further assessment of PKGmeasures in correlation with scales
for patient quality of life, sleep issues, both at night and
daytime sleepiness, impulse control disorder, and patient and
clinician impression of improvement.
Study limitations included a small sample size of patients,
per-protocol analysis, open label design, and no evaluation
of motor function after PKG-informed changes in therapy.
Additionally, we did not achieve our secondary endpoints of
Clinical Global Impression of Improvement (CGI-I) and Patient
Global Impression of Improvement (PGI-I) as only 16 patients
completed a follow up visit beyond baseline. Also, the PKG
system has limitations due to its ability to measure directly
only some of the motor manifestations of Parkinson’s disease,
which for many patients do not comprise the most troubling
symptoms. The PKG does measure overall bradykinesia, tremor
and dyskinesia but only on one side and does not directly
evaluate gait, freezing or falls. It remains to be determined with
further experience what non-motor symptoms may be indirectly
inferred from the PKG recordings or if it could be useful in
correlating motor symptoms with MCI subtypes (19). This in,
turn may help physicians determine how to best integrate PKG
data with patient symptom reporting and medical management
(15) or if objective measurement in routine care could improve
outcomes (16).
The PKG system provided clinical utility through improved
characterization of motor manifestations of Parkinson’s disease,
both the type and timing. This served to improve physician-
patient dialogue and provide insight to clinicians and patients
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to inform treatment impact and decisions. Additionally, patients
who wore the PKG watch felt the medication administration
reminders were valuable. Patients indicated the watch was easy
to use, performed as expected, and they would wear the PKG
again. Furthermore, patients were satisfied with PKG training,
usability and performance. Many patients found that the PKG
had a valuable impact on their care.
For optimal care of the PD patient, moving from sole
reliance upon subjective symptom reporting with office
based clinical examinations separated by weeks or months
to incorporation of objective measurements by wearable
devices is intuitively reasonable and increasingly supported
by several studies. In our experience and that of others use
of the PKG system has demonstrated value in care of the
PD patient.
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